Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 6
2011 2
2012 2
2013 4
2014 7
2015 8
2016 10
2017 8
2018 6
2019 4
2020 17
2021 13
2022 18
2023 17
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

120 results

Results by year

Filters applied: . Clear all
Page 1
Role of Lysine-Specific Demethylase 1 in Metabolically Integrating Osteoclast Differentiation and Inflammatory Bone Resorption Through Hypoxia-Inducible Factor 1α and E2F1.
Doi K, Murata K, Ito S, Suzuki A, Terao C, Ishie S, Umemoto A, Murotani Y, Nishitani K, Yoshitomi H, Fujii T, Watanabe R, Hashimoto M, Murakami K, Tanaka M, Ito H, Park-Min KH, Ivashkiv LB, Morinobu A, Matsuda S. Doi K, et al. Among authors: watanabe r. Arthritis Rheumatol. 2022 Jun;74(6):948-960. doi: 10.1002/art.42074. Epub 2022 Apr 27. Arthritis Rheumatol. 2022. PMID: 35077015 Free PMC article.
Comparative effectiveness of biological disease-modifying antirheumatic drugs and Janus kinase inhibitor monotherapy in rheumatoid arthritis.
Onishi A, Yamada H, Yamamoto W, Watanabe R, Hara R, Katayama M, Okita Y, Maeda Y, Amuro H, Son Y, Yoshikawa A, Hata K, Hashimoto M, Saegusa J, Morinobu A. Onishi A, et al. Among authors: watanabe r. Rheumatology (Oxford). 2023 Nov 21:kead620. doi: 10.1093/rheumatology/kead620. Online ahead of print. Rheumatology (Oxford). 2023. PMID: 37988163
Differential efficacy of TNF inhibitors with or without the immunoglobulin fragment crystallizable (Fc) portion in rheumatoid arthritis: the ANSWER cohort study.
Nakayama Y, Watanabe R, Murakami K, Murata K, Tanaka M, Ito H, Yamamoto W, Ebina K, Hata K, Hiramatsu Y, Katayama M, Son Y, Amuro H, Akashi K, Onishi A, Hara R, Yamamoto K, Ohmura K, Matsuda S, Morinobu A, Hashimoto M. Nakayama Y, et al. Among authors: watanabe r. Rheumatol Int. 2022 Jul;42(7):1227-1234. doi: 10.1007/s00296-021-05086-w. Epub 2022 Mar 10. Rheumatol Int. 2022. PMID: 35266034
IL-6 inhibitors and JAK inhibitors as favourable treatment options for patients with anaemia and rheumatoid arthritis: ANSWER cohort study.
Nakayama Y, Watanabe R, Yamamoto W, Ebina K, Hirano T, Kotani T, Shiba H, Katayama M, Son Y, Amuro H, Onishi A, Jinno S, Hara R, Murakami K, Murata K, Ito H, Tanaka M, Matsuda S, Morinobu A, Hashimoto M. Nakayama Y, et al. Among authors: watanabe r. Rheumatology (Oxford). 2024 Feb 1;63(2):349-357. doi: 10.1093/rheumatology/kead299. Rheumatology (Oxford). 2024. PMID: 37354495
120 results